A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
SI-BONE, Inc.
SIBN
$714M
Mkt Cap
$16.62
+0.91%
SI-BONE, Inc. (SIBN) has a 5-year average return on invested capital (ROIC) of -24.0%. This is below average and may indicate limited pricing power.
SI-BONE, Inc. (SIBN) has a market capitalization of $714M. It is classified as a small-cap stock.
SI-BONE, Inc. (SIBN) does not currently pay a regular dividend.
SI-BONE, Inc. (SIBN) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
SI-BONE, Inc. (SIBN) reported annual revenue of $201 million in its most recent fiscal year, based on SEC EDGAR filings.
SI-BONE, Inc. (SIBN) has a net profit margin of -9.4%. The company is currently unprofitable.
SI-BONE, Inc. (SIBN) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma. We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, sales agents and resellers in other countries. As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 201M | 201M | 167M | 139M | 106M | 90M |
| Net Income | -19M | -19M | -31M | -43M | -61M | -57M |
| EPS | $-0.44 | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 |
| Free Cash Flow | -9.1M | -9.1M | -23M | -27M | -51M | -46M |
| ROIC | -10.3% | -9.1% | -15.2% | -25.6% | -40.5% | -29.9% |
| Gross Margin | 79.6% | 79.6% | 79.0% | 78.8% | 46.0% | 50.4% |
| Debt/Equity | 0.21 | 0.21 | 0.22 | 0.23 | 0.40 | 0.30 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -22M | -22M | -35M | -47M | -60M | -52M |
| Operating Margin | -11.1% | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% |
| ROE | -10.6% | -11.0% | -18.4% | -32.4% | -52.6% | -37.2% |
| Shares Outstanding | 43M | 43M | 41M | 38M | 34M | 33M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 48M | 55M | 67M | 73M | 90M | 106M | 139M | 167M | 201M | 201M |
| Gross Margin | 5.7% | 11.5% | 89.9% | 87.9% | 50.4% | 46.0% | 78.8% | 79.0% | 79.6% | 79.6% |
| R&D | 5.5M | 5.4M | 7.3M | 9.5M | 12M | 14M | 15M | 17M | 17M | 17M |
| SG&A | 13M | 13M | 21M | 20M | 25M | 29M | 31M | 34M | 41M | 41M |
| EBIT | -17M | -12M | -36M | -39M | -52M | -60M | -47M | -35M | -22M | -22M |
| Op. Margin | -36.2% | -21.6% | -53.5% | -52.6% | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% | -11.1% |
| Net Income | -23M | -17M | -38M | -44M | -57M | -61M | -43M | -31M | -19M | -19M |
| Net Margin | -48.0% | -31.5% | -57.1% | -59.5% | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% | -9.4% |
| Non-Recurring | -214K | -52K | -171K | -376K | -399K | -153K | -1.3M | -1.9M | -1.6M | -1.6M |
| Returns on Capital | ||||||||||
| ROIC | -48.4% | -90.7% | -33.8% | -28.5% | -29.9% | -40.5% | -25.6% | -15.2% | -9.1% | -10.3% |
| ROE | 19.4% | 89.1% | -50.1% | -37.6% | -37.2% | -52.6% | -32.4% | -18.4% | -11.0% | -10.6% |
| ROA | -58.2% | -20.0% | -30.1% | -25.7% | -27.4% | -35.2% | -22.3% | -13.4% | -8.1% | -7.9% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -18M | -15M | -32M | -31M | -40M | -42M | -19M | -12M | -675K | -675K |
| Free Cash Flow | -18M | -15M | -34M | -33M | -46M | -51M | -27M | -23M | -9.1M | -9.1M |
| Owner Earnings | -20M | -18M | -40M | -44M | -58M | -68M | -48M | -43M | -32M | -32M |
| CapEx | 478K | 942K | 2.4M | 2.6M | 6.4M | 9.5M | 7.8M | 10M | 8.4M | 8.4M |
| Maint. CapEx | 1.0M | 722K | 774K | 1.1M | 2.1M | 3.5M | 5.4M | 4.4M | 5.8M | 5.8M |
| Growth CapEx | 0 | 220K | 1.7M | 1.4M | 4.3M | 6.1M | 2.4M | 6.1M | 2.6M | 2.6M |
| D&A | 1.0M | 722K | 774K | 1.1M | 2.1M | 3.5M | 5.4M | 4.4M | 5.8M | 5.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 73K | 38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.4M | 2.3M | 7.5M | 12M | 17M | 23M | 24M | 26M | 26M | 26M |
| Debt Repayment | 1.1M | 0 | 0 | 45M | 41M | 0 | 35M | 36M | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | 16M | -108M | -64M | -211M | -107M | -66M | -150M | -140M | -145M | -5.6M |
| Cash & Equiv. | 22M | 25M | 10M | 54M | 63M | 21M | 33M | 35M | 42M | 42M |
| Long-Term Debt | 39M | 39M | 35M | 39M | 35M | 35M | 36M | 35M | 36M | 36M |
| Debt/Equity | -0.30 | 0.43 | 0.62 | 0.23 | 0.30 | 0.40 | 0.23 | 0.22 | 0.21 | 0.21 |
| Interest Coverage | -2.8 | -2.3 | -7.3 | -6.3 | -9.6 | -21.1 | -13.6 | -10.2 | -8.5 | -8.5 |
| Equity | -129M | 90M | 63M | 169M | 134M | 98M | 169M | 167M | 178M | 178M |
| Total Assets | 36M | 139M | 117M | 223M | 191M | 158M | 230M | 230M | 239M | 239M |
| Total Liabilities | 165M | 48M | 54M | 54M | 56M | 59M | 61M | 63M | 61M | 61M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -140M | -157M | -196M | -239M | -296M | -357M | -400M | -431M | -450M | -450M |
| Working Capital | 26M | 127M | 93M | 205M | 159M | 116M | 188M | 181M | 191M | 191M |
| Current Assets | 34M | 136M | 111M | 218M | 176M | 138M | 211M | 208M | 216M | 216M |
| Current Liabilities | 7.5M | 9.0M | 19M | 13M | 17M | 21M | 23M | 27M | 25M | 25M |
| Per Share Data | ||||||||||
| EPS | -6.65 | -0.71 | -1.55 | -1.50 | -1.71 | -1.79 | -1.13 | -0.75 | -0.44 | -0.44 |
| Owner EPS | -5.77 | -0.72 | -1.61 | -1.50 | -1.77 | -1.99 | -1.26 | -1.04 | -0.74 | -0.74 |
| Book Value | -37.34 | 3.69 | 2.54 | 5.81 | 4.06 | 2.87 | 4.42 | 4.05 | 4.13 | 4.13 |
| Cash Flow/Share | -5.06 | -0.59 | -1.28 | -1.05 | -1.19 | -1.22 | -0.49 | -0.30 | -0.02 | -0.31 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 3.5M | 24.5M | 24.8M | 29.1M | 33.1M | 34.2M | 38.4M | 41.2M | 43.0M | 43.0M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -37.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 6.4 | 8.3 | 5.1 | 5.3 | 4.3 | 4.8 | 3.4 | 4.9 | 4.0 |
| Price/Sales | N/A | 9.7 | 6.8 | 7.7 | 10.1 | 5.5 | 5.8 | 3.8 | 3.5 | 3.6 |
| FCF Yield | N/A | -2.7% | -6.5% | -3.8% | -6.5% | -12.2% | -3.2% | -4.1% | -1.0% | -1.3% |
| Market Cap | N/A | 581M | 524M | 866M | 708M | 419M | 820M | 566M | 875M | 714M |
| Avg. Price | N/A | 18.88 | 18.39 | 19.51 | 27.52 | 17.08 | 20.86 | 15.40 | 16.55 | 16.62 |
| Year-End Price | N/A | 20.46 | 21.13 | 29.73 | 21.40 | 12.24 | 21.38 | 13.72 | 20.36 | 16.62 |
SI-BONE, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 66.8%.
SI-BONE, Inc. (SIBN) has a debt-to-equity ratio of 0.21. This indicates a conservatively financed balance sheet.
SI-BONE, Inc. (SIBN) reported earnings per share (EPS) of $-0.44 in its most recent fiscal year.
SI-BONE, Inc. (SIBN) has a return on equity (ROE) of -11.0%. A negative ROE may indicate losses or negative equity.
SI-BONE, Inc. (SIBN) has a 5-year average gross margin of 66.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for SI-BONE, Inc. (SIBN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SI-BONE, Inc. (SIBN) has a book value per share of $4.13, based on its most recent annual SEC filing.